In 2026, Alzheimer's testing split into two jobs: blood tests triage memory symptoms in primary care, while Tauklarify tau PET maps tau tangles in specialty centers. For primary-care patients, what comes next is blood-first testing, with PET or spinal fluid used to confirm positive results. Tauklarify (florquinitau F 18 injection) is a tracer drug injected before a brain scan. The scanner then lights up tau neurofibrillary tangles, the twisted tau proteins linked to Alzheimer's disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify adds
- Why blood tests moved first
- Can your regular doctor use them?
- What happens after a blood test?
What Tauklarify adds
The FDA approved Tauklarify for brain tau PET in cognitively impaired adults being evaluated for Alzheimer's disease to identify tau tangle pathology, according to the FDA 2026 approvals list. It gives doctors a direct picture of tangle location and spread. That picture helps stage disease and clarify an Alzheimer's evaluation.
A bright or clean scan alone does not settle the question. Practical Neurology reports that a positive or negative result alone does not independently confirm or exclude tau pathology and the scan is not for non-Alzheimer tauopathies, in Practical Neurology's August 2026 report. Doctors must read the image with symptoms, history, and other biomarkers. Tau PET also stays concentrated in specialized centers with approved tracers.
Why blood tests moved first
Blood tests measure phosphorylated tau, a blood signal tied to Alzheimer's amyloid and tau buildup. By late August 2026, four FDA-cleared options existed, as summarized by the Alzheimer's and Dementia Leader. They include Fujirebio Lumipulse pTau217 to amyloid-beta 42 ratio, Roche pTau181, C2N PrecivityAD2, and Roche pTau217.
The Roche pTau217 clearance drew attention because one cutoff set can both rule in and rule out amyloid pathology. Pharmacy Times described it as the first single-biomarker test to do both jobs, in Pharmacy Times' August 25, 2026 report. That design suits busy clinics. It reduces repeat testing and uncertain middle results for adults 55 and older with cognitive symptoms.
- Fujirebio Lumipulse: ratio test cleared May 2025
- Roche pTau181: cleared Oct. 2025
- C2N PrecivityAD2: cleared Aug. 20, 2026
- Roche Elecsys Phospho-Tau 217P: single-marker test cleared Aug. 24, 2026
Can your regular doctor use them?
Yes, with better accuracy than before. In a 1,300-patient study across 165 physicians, primary-care diagnostic accuracy rose from 65% to about 93% after seeing blood-biomarker results, matching specialists at about 90 to 94%, according to the Association's AAIC release. The gain came in real-world clinics. It reflects triage use, not a blood-only diagnosis.
Quality bars remain strict. The Alzheimer's Association's 2025 specialty-care guideline calls for at least 90% sensitivity and 75% specificity for triage tests and 90% for both in confirmatory use, as summarized by Technology Networks. A new 2026 primary-care decision-support tool presented at AAIC helps apply those bars. It guides when to test, refer, or confirm.
What happens after a blood test?
Expect a blood-first path. A low-risk result often leads to watchful follow-up and workup for other causes of confusion, sleep problems, or medication effects.
A high-risk result usually leads to referral and confirmation with PET or cerebrospinal fluid testing, consistent with joint EANM and SNMMI tau-PET recommendations. Blood tests are triage tools, not standalone diagnoses. Tau PET adds staging detail but requires travel, radiation exposure, and specialist reading.
- Bring specific examples of memory or thinking changes
- Ask what cutoff your clinic uses and what it means
- Ask whether a positive result needs PET or spinal-fluid confirmation
- Ask where tau PET is available if referral is needed
